English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

O presente artigo aborda os aspectos clínicos e socioeconômicos decorrentes da presença de dislipidemias em portadores de doenças cardiovasculares (DCV). Existem inúmeros estudos relacionados às DCV, uso de hipolipemiantes orais como as estatinas, e os aspectos econômicos envolvidos com impacto na área da saúde. Além de evidenciar a importância do tratamento das dislipidemias, o artigo busca demonstrar o ponto de vista farmacoeconômico, ou seja, dos custos gerados com o tratamento farmacológico desta patologia versus os custos decorrentes dos eventos cardiovasculares acometidos e suas consequências. Existe, portanto, relevante relação entre os impactos sociais decorrentes de incapacidade física e laborativa, aposentadorias precoces, entre outros custos importantes que poderiam ser evitados com uma análise econômica abrangente e eficiente realizada nos serviços de saúde do Brasil. Neste contexto, é enfatizada a importância da análise conjunta dos aspectos clínicos e socioeconômicos das dislipidemias que poderiam influenciar nas decisões das autoridades de saúde no momento da elaboração de protocolos clínicos de tratamentos farmacológicos a serem implementados no SUS. This paper discusses the clinical and socioeconomic factors arising from the presence of dyslipidemia in patients with cardiovascular disease (CVD). There are numerous studies related to CVD, oral use of statins as statins, and the economics aspects involved with an impact on health. In addition to demonstrating the importance of the treatment of dyslipidemia, the paper shows the pharmacoeconomic viewpoint, i.e. costs generated by the pharmacological treatment of this disease versus the costs of cardiovascular events and their consequences. There is therefore relevant relationship between the social impacts arising from physical disability and work, early retirements, among other important costs that could be avoided with a comprehensive economic analysis and efficient health services in Brazil. In this context, we emphasize the importance of joint analysis of the clinical and socioeconomic aspects of dyslipidemia that could influence the decisions of health authorities at the time of preparation of clinical protocols of pharmacological treatments to be implemented within the SUS

Aspectos clínicos e socioeconômicos das dislipidemias em portadores de doenças cardiovasculares